Developer of a clinical intelligence platform designed for continuous health monitoring, predictive analytics, and algor
Developer of a clinical intelligence platform designed for continuous health monitoring, predictive analytics, and algorithmic clinical insights.
Monitoring Equipment📍 Golden, COFounded 2019
Current Valuation
$1.2B
as of 2022-Q4
UNICORN
QL Price
$1.2B
0% vs last round
QuantLogix's current estimate for BioIntellisense, published 2026-11-12 — in line with the last disclosed round of $1.2B (2022-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.2B
2022-Q4
weight 0.07
How this price has held up
No round has priced for BioIntellisense since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-11-12 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, BioIntellisense, 2026-11-12 (0ecb716f3736c2e0).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is BioIntellisense going public?
No. BioIntellisense is private and has not filed to go public. There is no S-1 on file.
What is BioIntellisense's valuation in 2026?
BioIntellisense is valued at $1.2B as of 2022-Q4, set by its Early Stage VC ($178.6M, Dec 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has BioIntellisense filed an S-1?
No public S-1 is on file for BioIntellisense.
How much has BioIntellisense raised?
BioIntellisense has raised $260.6M in total, most recently a Early Stage VC of $178.6M in Dec 2022.
Is BioIntellisense publicly traded — can you buy BioIntellisense stock?
No. BioIntellisense is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for BioIntellisense on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2019
HQ
Golden, CO
Employees
89
Total Raised
$260.6M
Last Round
Early Stage VC — $178.6M (Dec 2022)
IPO Status
private
Fundraising Status
Early Stage VC · $178.6M · 3y 11mo ago
privateTotal raised $260.6M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Early Stage VC
$178.6M
Dec 2022
—
$1.2B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for BioIntellisense — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-11-12. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+50% vs 2026-09
Open roles
6
via lever
Product-build share
33%
engineering, research, product, design
Trajectory
scaling
balanced build + GTM — 33% builders vs 67% go-to-market/G&A — scaling both sides.
Executive bench growing while hiring expands: 1 senior hire (CEO); open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INEric MeizlishCEO · 2026-09-19
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Clinical Solutions ManagerFull Stack Data EngineerControllerCustomer Success Project ManagerDirector of Operations - Medical DeviceVice President, Growth
Counted from BioIntellisense's live job board as of 2026-10-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyMedical Device
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q4. Refreshed quarterly.